SWA
VRTX icon

Stratos Wealth Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Stratos Wealth Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-454
Closed -$206K – 688
2025
Q4 		$206K Buy
+454
New +$196K 0.01% 623
2025
Q3 		– Sell
-454
Closed -$202K – 713
2025
Q2 		$202K Buy
454
+27
+6% +$12.4K 0.01% 634
2025
Q1 		$207K Buy
+427
New +$199K 0.01% 623
2024
Q4 		– Sell
-560
Closed -$260K – 778
2024
Q3 		$260K Buy
560
+78
+16% +$37.5K 0.01% 639
2024
Q2 		$226K Buy
+482
New +$209K 0.01% 634

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Stratos Wealth Advisors's VRTX Position: Q1 2026 in Review

Stratos Wealth Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 454 shares — an estimated $206K sold.

Stratos Wealth Advisors first reported a position in VRTX in Q2 2024 and held it in 5 quarters. The position peaked at $260K in Q3 2024. 1,688 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Stratos Wealth Advisors reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Stratos Wealth Advisors sold 454 Vertex Pharmaceuticals shares in Q1 2026, an estimated $206K.
  • Stratos Wealth Advisors first reported a position in Vertex Pharmaceuticals in Q2 2024 and held it in 5 quarters.
  • Stratos Wealth Advisors's Vertex Pharmaceuticals position peaked at $260K in Q3 2024.
  • 1,688 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Stratos Wealth Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.